Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Shares Outstanding (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Shares Outstanding for 7 consecutive years, with $98.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 16.65% year-over-year to $98.0 million, compared with a TTM value of $98.0 million through Dec 2025, up 16.65%, and an annual FY2025 reading of $98.0 million, up 16.65% over the prior year.
  • Shares Outstanding was $98.0 million for Q4 2025 at aTYR PHARMA, roughly flat from $98.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $98.0 million in Q4 2025 and bottomed at $16.0 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $55.8 million, with a median of $57.8 million recorded in 2023.
  • The sharpest move saw Shares Outstanding skyrocketed 178.16% in 2021, then increased 4.39% in 2022.
  • Year by year, Shares Outstanding stood at $27.8 million in 2021, then rose by 6.14% to $29.5 million in 2022, then skyrocketed by 114.54% to $63.3 million in 2023, then soared by 32.79% to $84.0 million in 2024, then rose by 16.65% to $98.0 million in 2025.
  • Business Quant data shows Shares Outstanding for ATYR at $98.0 million in Q4 2025, $98.0 million in Q3 2025, and $92.9 million in Q2 2025.